Larimar Therapeutics, Inc.

Larimar Therapeutics (LRMR) has posted no cyber incidents or red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability in the recent period. However, low signal in a short window does not mean low risk; the company operates in biotech, where financing events and equity dilution cycles drive shareholder outcomes. The full $49 Report extends analysis to 12 months of SEC filings, adds a quantified dilution risk score, maps financing history, and flags AI-detected warning signals missed by headline scanning. The full $49 Report adds structural risk context that day-to-day filing snapshots cannot capture.